# A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

> **NCT03646604** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 35 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Upadacitinib (ABT-494)

## Key facts

- **NCT ID:** NCT03646604
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2024-08-29
- **Final completion:** 2024-08-29
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03646604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03646604, "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03646604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*